Benefit-Risk Analysis: When Medical Device Benefits Outweigh Remaining Risks

A device can help patients and still expose them to harm. A treatment may address a serious condition while carrying side effects, failure modes, or cybersecurity risks. Removing every risk is not a realistic condition for bringing useful medical technology to patients.

Benefit-risk analysis addresses that tension. The question is not simply whether releasing the device would help people. It is whether the expected benefits justify the remaining risks for a defined use, supported by evidence and after risk controls have been considered.

The FDA's Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications, issued August 30, 2019, explains the agency's approach for those pathways. That framework should not be confused with the substantial-equivalence standard for a 510(k). Cybersecurity evidence contributes to the assessment, but a vulnerability score cannot make the clinical decision.

Why This Matters

Patients can lose access to useful treatment when a device is withheld. They can also be harmed when a device reaches the market with risks that were poorly understood or inadequately controlled. A benefit-risk assessment must address both concerns without using urgency as a substitute for evidence.

The FDA's 2019 PMA and De Novo guidance considers the nature, magnitude, probability, and duration of benefits alongside the severity, probability, and duration of harms. It also considers uncertainty, patient perspectives, available alternatives, and risk mitigation. These factors depend on the specific device and clinical context, not a generic score threshold.

Cybersecurity belongs in that discussion when an attack can affect device safety or effectiveness. The FDA's Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, issued February 3, 2026, describes recommended security risk management and its connection to safety risk management. ISO 14971:2019 supplies the medical device risk management framework; ANSI/AAMI SW96 addresses security risk management for device manufacturers.

Blue Goat's experience informs the security side of that work: 275+ FDA submissions supported, zero cybersecurity rejections. That track record is not a forecast for another device. Each manufacturer's evidence, intended use, remaining risks, and applicable submission pathway still need their own assessment.

What does benefit-risk analysis actually compare?

Benefit-risk analysis compares expected patient benefits with the harms that can remain during the intended use of a device. It is not a calculation of commercial return, launch speed, or engineering convenience.

A benefit might be improved treatment, a more useful diagnosis, symptom relief, or better function. The assessment should explain how substantial that benefit is, who is expected to receive it, how often it occurs, and how long it lasts. Claims should follow the available clinical evidence.

Risk descriptions should identify the harm, the circumstances that could produce it, and the evidence supporting the estimate. Uncertainty belongs in the record. A lack of observed harm is not automatically evidence that harm is impossible.

The comparison does not require pretending that benefits and harms share a single numerical scale. The reasoning should be explicit enough that another reviewer can understand the evidence, assumptions, and decision.

How does ISO 14971 distinguish individual and overall residual risk?

ISO 14971 separates the remaining risk associated with a particular hazardous situation from the combined residual risk of the device. Passing individual risk evaluations does not, by itself, settle the overall evaluation.

For an individual residual risk outside the manufacturer's acceptability criteria, the process considers whether further risk control is practicable. Benefit-risk analysis addresses whether the benefits of intended use outweigh that residual risk when further control is not practicable. This is not a reason to bypass the risk-control process.

The overall residual risk evaluation considers the contributions of the remaining risks together, in relation to the benefits of intended use. The manufacturer applies the method and overall acceptability criteria established in the risk management plan. Multiple risks may interact, affect the same patients, or undermine the same clinical benefit.

The public preview of ISO 14971:2019 identifies benefit-risk analysis in clause 7.4 and overall residual risk evaluation in clause 8. Use the manufacturer's licensed standard for the complete requirements and implementation details.

Labeling and user information can communicate significant remaining risks. They should not be treated as an automatic substitute for a feasible design improvement or protective measure. The record needs to show why the selected controls fit the device and use environment.

Does the FDA use the same approach for every submission pathway?

No. The role of benefit-risk depends on the regulatory question and pathway, so one argument should not be copied unchanged across PMA, De Novo, and 510(k) submissions.

The FDA's PMA and De Novo guidance addresses benefit-risk determinations for those pathways. Patient preferences and tolerance for risk can contribute relevant evidence, particularly where treatment options are limited. That does not mean patient willingness to use a device establishes its safety or effectiveness.

For a 510(k), the central question remains substantial equivalence to a legally marketed predicate. The FDA's Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications (510(k)) with Different Technological Characteristics addresses a specific comparative context. It does not replace the 510(k) review standard.

See also: Is a PHI Breach Patient Harm? How the FDA Views Device Data Confidentiality, Premarket Cybersecurity in Your QMS: ISO 13485 & QMSR, and Design FMEA for Medical Devices: dFMEA.

For more on the pathway distinction, read 510(k), De Novo, and PMA differences.

Can an unmet patient need justify remaining cybersecurity risk?

Unmet need can inform benefit-risk reasoning, but it does not automatically justify an unresolved vulnerability. The assessment must connect the security issue to actual device behavior, clinical consequences, available controls, and the uncertainty that remains.

Start with the technical finding. Determine whether the vulnerable function is present and reachable in the device's configuration. Assess exploitability and the effect on confidentiality, integrity, or availability, then identify whether that effect has a credible path to patient harm.

Where a safety consequence exists, the manufacturer's clinical and risk teams determine the relevant harm severity using the device's safety risk analysis. A CVSS base score is not a clinical severity score. A high security impact and a severe patient harm are different conclusions supported by different evidence.

Compare the risk before and after controls. Evidence might include a verified access restriction, a corrected implementation, or testing of an update mechanism. A control that exists only in a plan does not establish that it works in the released configuration.

The argument must also account for lifecycle duties. Section 524B of the FD&C Act establishes cybersecurity requirements for covered cyber-device submissions, including vulnerability management planning, specified update and patch processes, and an SBOM. A favorable clinical benefit-risk assessment does not waive those obligations.

See how ISO 14971 and cybersecurity risk management connect for the handoff between security evidence and the safety risk file.

Who should make and document the decision?

The manufacturer owns the risk management decision and its supporting clinical rationale. Security specialists provide evidence and recommendations, not an independent authorization to release a medical device.

Engineering explains the configuration, attack paths, and controls. Cybersecurity reviewers assess security consequences and verification results. Clinical specialists evaluate the intended benefits and potential patient harms, while quality and regulatory staff maintain the decision record and submission context.

The record should identify the people responsible for review and approval under the manufacturer's procedures. It should state what was evaluated, which criteria applied, what evidence was used, what limitations remain, and what monitoring or follow-up is planned. Preserve traceability to the underlying findings and risk controls.

Avoid writing that a testing provider has accepted clinical risk on the manufacturer's behalf. Also avoid calling a documented justification proof that the FDA will agree. The agency's decision remains separate from the manufacturer's internal assessment.

How Blue Goat Cyber Approaches This

Blue Goat supports the security evidence that feeds the manufacturer's benefit-risk assessment. We identify attack paths, assess exploitability and security impact, and test the controls for the device and interfaces in scope. We keep technical security findings separate from clinical benefit claims.

Our documented method uses CVSS v4.0 factors and security risk matrices. Where a finding can reach a patient, we use harm severity supplied by the manufacturer's ISO 14971 hazard analysis. We do not invent safety severity, assign clinical benefits, or decide that a manufacturer's device should reach the market.

Our team includes CISSP-certified testing leadership. The work connects findings, control verification, and remaining risk so the manufacturer's clinical, quality, and regulatory teams can review the evidence together. Assumptions and limitations stay visible rather than being hidden by a favorable score.

Medical device cybersecurity consulting can help organize that handoff. Medical device penetration testing supplies evidence about the security controls in scope. The manufacturer retains ownership of risk acceptance and the overall benefit-risk conclusion.

Frequently Asked Questions

What is benefit-risk analysis for a medical device?

Benefit-risk analysis evaluates expected clinical benefits against the remaining risks for the device's intended use and patients. It relies on evidence about benefits, harms, controls, and uncertainty. ISO 14971 distinguishes individual residual risk analysis from overall residual risk evaluation. The manufacturer documents its assessment, and the FDA considers benefit-risk within the applicable regulatory framework rather than treating that assessment as an authorization.

Is risk-benefit analysis the same term?

Risk-benefit analysis is commonly understood to mean the same general comparison. Benefit-risk analysis is the wording used in ISO 14971 and in the FDA guidance discussed here. Consistent terminology helps keep the risk management file readable. More important than the word order is explaining the intended use, evidence, residual risks, decision criteria, and responsibility for the assessment.

Can a medical device reach the market with remaining risks?

Medical devices can have remaining risks after controls are implemented. The manufacturer still needs to evaluate those risks under its risk management process and meet the applicable regulatory requirements. A documented benefit-risk assessment can support the relevant decision, but it does not establish authorization. The intended patients, clinical benefits, alternatives, evidence limitations, and pathway all affect the assessment.

Does benefit-risk analysis allow a manufacturer to leave cybersecurity findings unresolved?

A favorable benefit-risk argument does not automatically justify leaving a security finding unresolved. The manufacturer needs to assess the finding in the actual configuration, consider further risk controls, verify selected controls, and evaluate the remaining consequences. Applicable section 524B duties remain in place for covered cyber devices. A security score alone cannot show that clinical benefits outweigh potential patient harms.

Who owns the clinical benefit-risk decision?

The manufacturer owns the documented assessment through its designated clinical, quality, regulatory, and risk management responsibilities. Cybersecurity specialists contribute technical findings and control evidence. They do not replace clinical judgment or accept patient risk on the manufacturer's behalf. The FDA makes the applicable premarket regulatory decision, which remains distinct from the manufacturer's internal risk acceptance and release procedures.

CTA

To connect technical findings with patient safety, start with the ISO 14971 and cybersecurity risk management guide. Use it with your device's hazard analysis and security evidence. Keep clinical benefits, security impact, and manufacturer risk acceptance distinct so each conclusion has an identifiable owner and supporting record.